Barclays Initiates BioMarin Pharmaceutical With Overweight By: Benzinga via Benzinga June 05, 2015 at 08:39 AM EDT Analysts at Barclays initiated coverage on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) with a Overweight rating. The target price for ... Read More >> Related Stocks: Biomarin Pharmaceuticals